{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T11:18:41Z","timestamp":1783682321530,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271302"],"award-info":[{"award-number":["82271302"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ejphar.2026.178777","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T23:30:27Z","timestamp":1773531027000},"page":"178777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Evolocumab alleviates atherogenesis by inhibiting inflammation-mediated endothelial cell activation via the PI3K\/AKT\/NF-\u03baB pathway"],"prefix":"10.1016","volume":"1020","author":[{"given":"Chao","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui-jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-hai","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-wen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-hang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2026.178777_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156064","article-title":"PCSK9 in metabolism and diseases","volume":"163","author":"Ajoolabady","year":"2025","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2026.178777_bib2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.molcel.2014.08.024","article-title":"NF-kappaB directs dynamic super enhancer formation in inflammation and atherogenesis","volume":"56","author":"Brown","year":"2014","journal-title":"Mol Cell"},{"key":"10.1016\/j.ejphar.2026.178777_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110370","article-title":"Fucoxanthin alleviated atherosclerosis by regulating PI3K\/AKT and TLR4\/NFkappaB mediated pyroptosis in endothelial cells","volume":"120","author":"Cui","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejphar.2026.178777_bib4","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1126\/science.1990440","article-title":"Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis","volume":"251","author":"Cybulsky","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2026.178777_bib5","doi-asserted-by":"crossref","first-page":"531","DOI":"10.7150\/thno.80289","article-title":"SIRT3 mediates the effects of PCSK9 inhibitors on inflammation, autophagy, and oxidative stress in endothelial cells","volume":"13","author":"D'Onofrio","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.ejphar.2026.178777_bib6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/1054-8807(94)90005-1","article-title":"Frequency, extent, and distribution of endomyocardial adipose tissue: morphometric analysis of endomyocardial biopsy specimens from 241 patients","volume":"3","author":"Dembinski","year":"1994","journal-title":"Cardiovasc. Pathol."},{"key":"10.1016\/j.ejphar.2026.178777_bib7","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/cvr\/cvv178","article-title":"Cross-talk between LOX-1 and PCSK9 in vascular tissues","volume":"107","author":"Ding","year":"2015","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejphar.2026.178777_bib8","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.bbrc.2008.07.023","article-title":"Inflammation stimulates the expression of PCSK9","volume":"374","author":"Feingold","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2026.178777_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.154684","article-title":"Hydroxysafflor yellow A regulates lymphangiogenesis and inflammation via the inhibition of PI3K on regulating AKT\/mTOR and NF-kappaB pathway in macrophages to reduce atherosclerosis in ApoE-\/- mice","volume":"112","author":"Feng","year":"2023","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ejphar.2026.178777_bib10","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1007\/s11427-023-2688-8","article-title":"Increase of PCSK9 expression in diabetes promotes VEGFR2 ubiquitination to inhibit endothelial function and skin wound healing","volume":"67","author":"Gao","year":"2024","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.ejphar.2026.178777_bib11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1749-6632.1987.tb33025.x","article-title":"Vascular endothelium: nature's blood-compatible container","volume":"516","author":"Gimbrone","year":"1987","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejphar.2026.178777_bib12","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1161\/CIRCRESAHA.115.306301","article-title":"Endothelial cell dysfunction and the pathobiology of atherosclerosis","volume":"118","author":"Gimbrone","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2026.178777_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.888390","article-title":"The endothelium as a hub for cellular communication in atherogenesis: is there directionality to the message?","volume":"9","author":"Howe","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.ejphar.2026.178777_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108480","article-title":"Targeting PCSK9 to tackle cardiovascular disease","volume":"249","author":"Hummelgaard","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2026.178777_bib15","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI122440","article-title":"c-Abl regulates YAPY357 phosphorylation to activate endothelial atherogenic responses to disturbed flow","volume":"129","author":"Li","year":"2019","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejphar.2026.178777_bib16","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.3892\/mmr.2017.6803","article-title":"Investigation of highly expressed PCSK9 in atherosclerotic plaques and ox-LDL-induced endothelial cell apoptosis","volume":"16","author":"Li","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejphar.2026.178777_bib17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00395-025-01100-5","article-title":"Evolocumab attenuates myocardial ischemia\/reperfusion injury by blocking PCSK9\/LIAS-mediated cuproptosis of cardiomyocytes","volume":"120","author":"Li","year":"2025","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.ejphar.2026.178777_bib18","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","article-title":"The changing landscape of atherosclerosis","volume":"592","author":"Libby","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2026.178777_bib19","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1161\/CIRCRESAHA.116.308334","article-title":"Atherosclerosis: successes, surprises, and future challenges","volume":"118","author":"Libby","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2026.178777_bib20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11064-024-04272-z","article-title":"Inhibition of PCSK9 protects against cerebral ischemia\u2012reperfusion injury via attenuating microcirculatory dysfunction","volume":"50","author":"Luo","year":"2024","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.ejphar.2026.178777_bib21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2026.178777_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.139066","article-title":"Mechanisms underlying the effects of the conditional knockdown of hepatic PCSK9 in attenuating lipopolysaccharide-induced acute liver inflammation","volume":"291","author":"Miao","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejphar.2026.178777_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116314","article-title":"PCSK9 aggravated carotid artery stenosis in ApoE(-\/-) mice by promoting the expression of tissue factors in endothelial cells via the TLR4\/NF-kappaB pathway","volume":"225","author":"Peng","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.178777_bib24","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/ATVBAHA.123.320391","article-title":"Disruption of PCSK9 suppresses inflammation and attenuates abdominal aortic aneurysm formation","volume":"45","author":"Peng","year":"2025","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejphar.2026.178777_bib25","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023328","article-title":"Effects of PCSK9 targeting: alleviating oxidation, inflammation, and atherosclerosis","volume":"11","author":"Punch","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ejphar.2026.178777_bib26","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/s41569-023-00883-1","article-title":"Flow-induced reprogramming of endothelial cells in atherosclerosis","volume":"20","author":"Tamargo","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ejphar.2026.178777_bib27","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3892\/ijmm.2012.1072","article-title":"PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-kappaB activation in THP-1-derived macrophages","volume":"30","author":"Tang","year":"2012","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ejphar.2026.178777_bib28","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1002\/jcp.27254","article-title":"PCSK9: a novel inflammation modulator in atherosclerosis?","volume":"234","author":"Tang","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ejphar.2026.178777_bib29","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.atherosclerosis.2017.04.023","article-title":"New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4\/NF-kappaB pathway","volume":"262","author":"Tang","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejphar.2026.178777_bib30","first-page":"2098","article-title":"Inhibition of proprotein convertase subtilisin\/kexin type 9 attenuates neuronal apoptosis following focal cerebral ischemia via apolipoprotein E receptor 2 downregulation in hyperlipidemic mice","volume":"42","author":"Wang","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ejphar.2026.178777_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.894789","article-title":"Targeting PCSK9 ameliorates graft vascular disease in mice by inhibiting NLRP3 inflammasome activation in vascular smooth muscle cells","volume":"13","author":"Zou","year":"2022","journal-title":"Front. Immunol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926002591?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926002591?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T19:41:21Z","timestamp":1776109281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926002591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":31,"alternative-id":["S0014299926002591"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178777","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolocumab alleviates atherogenesis by inhibiting inflammation-mediated endothelial cell activation via the PI3K\/AKT\/NF-\u03baB pathway","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.178777","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"178777"}}